Inbrija (levodopa) is a prescription inhaler used to treat Parkinson’s disease. Inbrija’s cost may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use.

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ...

inbrija-1 Inbrija, the first inhaled levodopa, has been made available by Acorda Therapeutics for the intermittent treatment of OFF episodes in patients with Parkinson disease treated with ...

Under the agreement, Merz Therapeutics will receive upfront, development and commercial milestone payments, and tiered supply and royalty arrangements, with no manufacturing rights granted to Kvvit ...

Approval of the home-grown Arcus delivery technology deployed by Ardsley, N.Y.-based Acorda Therapeutics Inc. with Inbrija (levodopa inhalation powder) represents "a tremendous step forward" for the ...

inbrija-1 Inbrija (levodopa inhalation powder; Acorda Therapeutics) is the first and only FDA-approved inhaled levodopa for intermittent treatment of OFF episodes in patients with Parkinson's disease ...

Acorda Therapeutics has launched a streaming commercial for Inbrija, a four-year-old rescue inhaler for Parkinson’s sufferers, delivered only to viewers who have self-identified as being impacted in ...

ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a ...

RALEIGH, N.C.--(BUSINESS WIRE)--Merz Therapeutics North America today announced the launch of 'Celebrating the Fighters,' a nationwide campaign that honors the fighting spirit of people living with ...

Merz Therapeutics GmbH and Jiangxi Kvvit Pharmaceutical Co. Ltd. today announced that the companies have entered into an exclusive license and collaboration agreement regarding INBRIJA® (levodopa ...